

# Accepted Manuscript

Title: Impact of Dose Adjusted Melphalan in Obese Patients Undergoing Autologous Stem Cell Transplantation

Author: Kendall Shultes, Christopher Arp, Keith Stockerl-Goldstein, Kathryn Trinkaus, Sean DeFrates


PII: S1083-8791(17)31163-1  
DOI: <https://doi.org/10.1016/j.bbmt.2017.11.041>  
Reference: YBBMT 54912

To appear in: *Biology of Blood and Marrow Transplantation*

Received date: 13-10-2017  
Accepted date: 30-11-2017

Please cite this article as: Kendall Shultes, Christopher Arp, Keith Stockerl-Goldstein, Kathryn Trinkaus, Sean DeFrates, Impact of Dose Adjusted Melphalan in Obese Patients Undergoing Autologous Stem Cell Transplantation, *Biology of Blood and Marrow Transplantation* (2017), <https://doi.org/10.1016/j.bbmt.2017.11.041>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



**Impact of Dose Adjusted Melphalan in Obese Patients Undergoing Autologous Stem Cell  
Transplantation**

**Kendall Shultes, Pharm.D.<sup>1</sup>, Christopher Arp, Pharm.D.<sup>2</sup>, Keith Stockerl-Goldstein, MD<sup>3</sup>,  
Kathryn Trinkaus, Ph.D.<sup>4</sup>, Sean DeFrates, Pharm.D., BCOP<sup>5</sup>**

Barnes-Jewish Hospital, Department of Pharmacy, St. Louis, MO<sup>1</sup>, Carolinas Medical Center, Charlotte, NC<sup>2</sup>, Washington  
University Department of Oncology, St. Louis, MO<sup>3</sup>, Washington University School of Medicine, Biostatistics Shared Resource,  
Siteman Cancer Center, St. Louis, MO<sup>4</sup>, Northwestern Memorial Hospital, Chicago, IL<sup>5</sup>

**Corresponding Author**

Kendall C. Shultes, Pharm.D.  
Barnes-Jewish Hospital  
216 S. Kingshighway Blvd.  
St. Louis, MO 63110  
Phone: (314) 576-5471  
Fax number: (314) 747-8180  
Email: kcshultes06@gmail.com

**Short Title:** Dose Adjusted Melphalan in ASCT

**Financial Disclosure Statement:** No funding was provided for this study and none of the authors have any conflicts of interest to disclose.

**Highlights**

- Dose adjusted melphalan outcomes in autologous stem cell transplantation.
- Adjusted body weight used in BSA if weight greater than 120% ideal body weight.
- 3-year EFS 51% obese versus 40% non-obese cohort met non-inferiority ( $p=0.0025$ ).
- Suggests transplant efficacy is not affected by AdBW dosing in obese patients.
- Future studies needed for insight into best dosing practice for obese patients.

**Abstract**

**Background:** Limited guidance exists for dosing melphalan (MEL) for autologous stem cell transplantation (ASCT) in the obese patient population as the current literature reports conflicting clinical

Download English Version:

<https://daneshyari.com/en/article/8429968>

Download Persian Version:

<https://daneshyari.com/article/8429968>

[Daneshyari.com](https://daneshyari.com)